Beijing Tong Ren Tang Chinese Medicine Company (3613) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
14 Aug, 2026Executive summary
Announcement discloses that unaudited financial information for the first quarter of 2026 has been published by the controlling shareholder, Tong Ren Tang Technologies, covering the period ended 31 March 2026.
Shareholders and investors are advised to exercise caution when dealing in the company's securities.
Significant events and developments
Tong Ren Tang Technologies, the controlling shareholder, released unaudited Q1 2026 financial information on the Hong Kong Stock Exchange.
Beijing Tong Ren Tang Company Limited, the ultimate controlling shareholder, will announce its Q1 2026 unaudited results on or before 30 April 2026 on the Shanghai Stock Exchange.
Risk factors and uncertainties
Caution is advised for shareholders and potential investors regarding trading in the company's securities.
Latest events from Beijing Tong Ren Tang Chinese Medicine Company
- Revenue and profit fell, but cash and equity rose; global expansion and innovation prioritized.3613
Q4 2025 - Controlling shareholder released unaudited nine-month 2024 results; caution advised.3613Q3 2024
- Q1 2025 unaudited results released by the controlling shareholder; caution advised.3613Q1 2025
- Controlling shareholder released unaudited 9-month 2025 results; parent to follow by 31 Oct.3613Q3 2025
- Revenue and profit rose, driven by expansion, innovation, and strong cash position.3613Q2 2025
- Revenue and profit fell over 17% year-over-year, but liquidity and R&D investment stayed strong.3613Q2 2024
- Revenue up 5.7% but net profit down 10.4% as Overseas sales fell and costs rose.3613Q4 2024